Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

By W. Sandborn, C. Gasink, Long-Long Gao, M. Blank, J. Johanns, C. Guzzo, Bruce E. Sands, S. Hanauer, S. Targan, P. Rutgeerts and 7 more. New England Journal of Medicine, 2012

1,077 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Rheumatology

View Paper: https://www.semanticscholar.org/paper/f0cd02b8c3ede50679980c2759bd487b3f626c42

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Ta-Chiang Liu
2. T. Stappenbeck

Citations in the corpus

• GENETICS AND PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE (2016, background): “Indeed, ustekinumab, a monoclonal antibody targeting IL12 and IL23, shows great promise in CD (51).”